MarketBeat on MSN
CRISPR Therapeutics enters 'second phase' as CASGEVY momentum builds, pipeline data looms
3 Biotech Stocks That Could Benefit from the Patent Cliff CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam ...
Researchers from the Broad Institute used a precision genome-editing tool to switch off the production of the misfolded ...
The new CRISPR platform, called ΨDNA, reprograms Cas12 nucleases to recognize and act on RNA using a DNA-based guide scaffold ...
A team of engineers at the University of Florida has developed a new form of CRISPR technology that could make diagnostics ...
Immune cell therapies have transformed the treatment of certain blood cancers over the past decade. However, when it comes to ...
Presented improved editing data in non-human primates (NHP) for sickle cell disease (SCD), demonstrating a single dose of Gene Writer achieved an average of 85% of long-term hematopoietic stem cells ...
In an oral presentation at ASGCT, Editas reported that a single dose of EDIT-401 achieved ≥90 percent mean LDL-C reduction across all dose groups in non-human primates (NHPs). ≥90 percent mean LDL-C ...
Gene editing can repair a DNA error in mice that causes Dravet syndrome, a rare, incurable, and potentially deadly form of ...
In a world first, a research team at the University of Zurich has successfully treated mice carrying an inherited form of ...
Researchers develop LinCx, a biological "wire" that creates precision electrical bypasses in the brain to restore function without drugs or external stimulation.
Allogeneic hematopoietic cell transplantation (alloHCT) using tremtelectogene empogeditemcel (trem-cel), a CRISPR–Cas9–edited ...
Agreement strengthens Aurigene's discovery platforms with access to foundational CRISPR/Cas9 intellectual property, enabling responsible innovation and enhanced global partner supportDUBLIN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results